Summary The survival of 616 women aged 15-59 with breast cancer, 226 of whom had been taught and practised breast self examination (BSE) prior to diagnosis and 390 of whom had not, is reported. Six year survival rates were 73.1% in the BSE taught group and 66.1% in other women (P = 0.07).
Summary The survival of 616 women aged 15-59 with breast cancer, 226 of whom had been taught and practised breast self examination (BSE) prior to diagnosis and 390 of whom had not, is reported. Six year survival rates were 73.1% in the BSE taught group and 66.1% in other women (P = 0.07).
In a previously reported investigation of 616 women with breast cancer included in a case-control study, we found an association between tumour stage at presentation and breast self examination (BSE) (Mant et al., 1987) . Women 
Results
There were 130 deaths in the group that had never been taught BSE and 60 in the group that had been taught and practised BSE. The overall difference in survival is shown in Figure 1 . The two survival curves began to diverge after year 1 with overall survival at the end of year 6 of 66.1% in the non-taught group and 73.1% in the BSE taught group. This is consistent with a lead time of about 18 months. The difference between the curves just fails to reach conventional levels of statistical significance (P = 0.07). Figure 2 shows survival according to stage; the survival benefit of taught BSE appears largely to be limited to patients with stage 1 disease, although the confidence intervals on the survival rates for stages 2-4 are wide.
Discussion
In the women studied here the improvement in stage at diagnosis is carried through to increased survival at 6 years. There is a 7% probability that a difference as extreme as this would be seen by chance, even if there was no real difference in survival between the two groups. However, the more important uncertainty stems from the inability of a follow-up study to Figure 2 Survival of women according to whether or not they had been taught BSE stratified by disease stage at diagnosis.
and, unlike the UKTEDBC, this study does not allow a direct measurement of the effect on mortality of early diagnosis resulting from teaching BSE. It is still possible that many of the cancers diagnosed in the BSE taught group had metastasised haematologically at diagnosis and the increase in survival seen reflects only advancement of diagnosis (i.e. lead time). However the fact that the survival benefit is essentially limited to patients with early stage tumours is consistent with an early treatment effect and while the survival benefit is sustained, the possibility that BSE is effective cannot be dismissed. As a definitive randomised trial now seems unlikely, perhaps we should accept that some women may extend their lives through BSE, although women should be made aware that if there is any benefit it is small in comparison to mammographic screening. The cost of BSE, particularly the anxiety experienced because of advancement of diagnosis and of false positive results in younger women, weighs heavily in formulating public health policy, and we still do not believe that BSE should be promoted as a means of screening for breast cancer.
